Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MENABCWY-1GEN
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MENABCWY-1GEN is a combined meningococcal vaccine developed by GlaxoSmithKline. It is designed to provide protection against invasive meningococcal disease (IMD) caused by five different serogroups of *Neisseria meningitidis*: A, B, C, W, and Y. The vaccine works by inducing an immune response to antigens from these serogroups. It is administered intramuscularly and is currently in Phase II clinical trials for healthy infants.
- Brand names
- Penmenvy
- Other names
- meningococcal group A, B, C, W and Y vaccine, second generationpentavalent meningococcal vaccineMenABCWY vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)fHbp (Factor H-binding protein)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideNadA (Neisserial adhesin A)NHBA (Neisserial heparin-binding antigen)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)MenB OMV (Neisseria meningitidis serogroup B outer membrane vesicle)
Beyond the preview
Go deeper on MENABCWY-1GEN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MENABCWY-1GEN.